m-PEG7-CH2CH2CHO features a PEG7 linker with terminal aldehyde functionality, enabling selective oxime ligation in ADC synthesis. This linker improves conjugation specificity and stability for targeted antibody-drug conjugate payload delivery.
Structure of 1234369-95-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
m-PEG7-CH2CH2CHO, a small molecule frequently employed as a functional linker in diverse bioscience and pharmaceutical settings, finds utility in various applications.
Drug Delivery Systems: Within drug conjugation processes, m-PEG7-CH2CH2CHO plays a pivotal role in enhancing the solubility and stability of therapeutic agents. Serving as a critical linker, it facilitates the attachment of drugs to polymers, thereby augmenting their circulation time and bioavailability. This structural modification is indispensable for crafting more efficacious drug delivery systems capable of targeting specific tissues or cells with precision.
Bioconjugation: At the intersection of chemistry and biology, m-PEG7-CH2CH2CHO finds application in bioconjugation to alter proteins, antibodies, and other biomolecules. Leveraging the aldehyde group within m-PEG7-CH2CH2CHO, stable linkages can be forged with amines on biomolecules, enabling site-specific labeling or immobilization.
Surface Modification: In the domain of biotechnology and medical devices, m-PEG7-CH2CH2CHO serves as a key player in surface modification processes. By engaging with substrates, it imparts non-fouling and hydrophilic characteristics to surfaces, effectively curtailing protein adsorption and cell adhesion. This attribute proves advantageous in the creation of biocompatible surfaces ideal for implants and sensor technologies.
Nanoparticle Functionalization: In the world of nanotechnology, m-PEG7-CH2CH2CHO assumes a crucial role in the functionalization of nanoparticles, heightening their biocompatibility and stability within biological environments. Harnessing its PEG moiety, it bestows a stealth effect upon nanoparticles, diminishing immunogenicity and prolonging their circulation within the body. This advancement lays the foundation for the successful development of nanoparticles tailored for precise drug delivery and imaging applications, pushing forward the frontier of nanomedicine.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00875 | m-PEG6-SS-PEG6-methyl | 1007386-15-3 | |
BADC-00512 | m-PEG1-NHS ester | 1027371-75-0 | |
BADC-00878 | mPEG6-azide | 1043884-49-6 | |
BADC-00882 | m-PEG5-succinimidyl carbonate | 1058691-00-1 | |
BADC-00883 | mPEG7-aldehyde | 1058691-77-2 | |
BADC-00884 | m-PEG8-Ms | 1059588-19-0 | |
BADC-00889 | m-PEG8-COOH | 1093647-41-6 | |
BADC-00890 | mPEG4-bromide | 110429-45-3 | |
BADC-00519 | m-PEG2-NHS ester | 1127247-34-0 | |
BADC-00920 | m-PEG4-Ms | 130955-37-2 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.